Vaccine-mediated immunity against dengue and the potential for long-term protection against disease

    Research output: Contribution to journalArticle

    15 Citations (Scopus)

    Abstract

    It is estimated that over 2.5 billion people are at risk for contracting dengue, a virus responsible for 50-390 million infections in addition to thousands of hospitalizations and deaths each year. There are no licensed vaccines available to combat this pathogen but substantial efforts are underway to develop live-attenuated, inactivated, and subunit vaccines that will protect against each of the four serotypes of dengue. Unfortunately, the results of a recent Phase IIb efficacy trial involving a tetravalent live-attenuated chimeric dengue virus vaccine have raised questions with regard to our current understanding of vaccine-mediated immunity to this important flavivirus. Here, we will briefly summarize these vaccination efforts and discuss the importance of informative in vivo models for determining vaccine efficacy and the need to establish a quantitative correlate of immunity in order to predict the duration of vaccine-induced antiviral protection.

    Original languageEnglish (US)
    Article number195
    JournalFrontiers in Immunology
    Volume5
    Issue numberMAY
    DOIs
    StatePublished - 2014

    Fingerprint

    Dengue
    Immunity
    Vaccines
    Dengue Virus
    Dengue Vaccines
    Flavivirus
    Attenuated Vaccines
    Inactivated Vaccines
    Subunit Vaccines
    Antiviral Agents
    Vaccination
    Hospitalization
    Infection

    Keywords

    • Antibody
    • Correlates of immunity
    • Dengue
    • Immunological memory
    • Vaccines

    ASJC Scopus subject areas

    • Immunology
    • Immunology and Allergy

    Cite this

    Vaccine-mediated immunity against dengue and the potential for long-term protection against disease. / Slifka, Mark.

    In: Frontiers in Immunology, Vol. 5, No. MAY, 195, 2014.

    Research output: Contribution to journalArticle

    @article{ee581d4878274fa284f1090e85132235,
    title = "Vaccine-mediated immunity against dengue and the potential for long-term protection against disease",
    abstract = "It is estimated that over 2.5 billion people are at risk for contracting dengue, a virus responsible for 50-390 million infections in addition to thousands of hospitalizations and deaths each year. There are no licensed vaccines available to combat this pathogen but substantial efforts are underway to develop live-attenuated, inactivated, and subunit vaccines that will protect against each of the four serotypes of dengue. Unfortunately, the results of a recent Phase IIb efficacy trial involving a tetravalent live-attenuated chimeric dengue virus vaccine have raised questions with regard to our current understanding of vaccine-mediated immunity to this important flavivirus. Here, we will briefly summarize these vaccination efforts and discuss the importance of informative in vivo models for determining vaccine efficacy and the need to establish a quantitative correlate of immunity in order to predict the duration of vaccine-induced antiviral protection.",
    keywords = "Antibody, Correlates of immunity, Dengue, Immunological memory, Vaccines",
    author = "Mark Slifka",
    year = "2014",
    doi = "10.3389/fimmu.2014.00195",
    language = "English (US)",
    volume = "5",
    journal = "Frontiers in Immunology",
    issn = "1664-3224",
    publisher = "Frontiers Media S. A.",
    number = "MAY",

    }

    TY - JOUR

    T1 - Vaccine-mediated immunity against dengue and the potential for long-term protection against disease

    AU - Slifka, Mark

    PY - 2014

    Y1 - 2014

    N2 - It is estimated that over 2.5 billion people are at risk for contracting dengue, a virus responsible for 50-390 million infections in addition to thousands of hospitalizations and deaths each year. There are no licensed vaccines available to combat this pathogen but substantial efforts are underway to develop live-attenuated, inactivated, and subunit vaccines that will protect against each of the four serotypes of dengue. Unfortunately, the results of a recent Phase IIb efficacy trial involving a tetravalent live-attenuated chimeric dengue virus vaccine have raised questions with regard to our current understanding of vaccine-mediated immunity to this important flavivirus. Here, we will briefly summarize these vaccination efforts and discuss the importance of informative in vivo models for determining vaccine efficacy and the need to establish a quantitative correlate of immunity in order to predict the duration of vaccine-induced antiviral protection.

    AB - It is estimated that over 2.5 billion people are at risk for contracting dengue, a virus responsible for 50-390 million infections in addition to thousands of hospitalizations and deaths each year. There are no licensed vaccines available to combat this pathogen but substantial efforts are underway to develop live-attenuated, inactivated, and subunit vaccines that will protect against each of the four serotypes of dengue. Unfortunately, the results of a recent Phase IIb efficacy trial involving a tetravalent live-attenuated chimeric dengue virus vaccine have raised questions with regard to our current understanding of vaccine-mediated immunity to this important flavivirus. Here, we will briefly summarize these vaccination efforts and discuss the importance of informative in vivo models for determining vaccine efficacy and the need to establish a quantitative correlate of immunity in order to predict the duration of vaccine-induced antiviral protection.

    KW - Antibody

    KW - Correlates of immunity

    KW - Dengue

    KW - Immunological memory

    KW - Vaccines

    UR - http://www.scopus.com/inward/record.url?scp=84899995071&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84899995071&partnerID=8YFLogxK

    U2 - 10.3389/fimmu.2014.00195

    DO - 10.3389/fimmu.2014.00195

    M3 - Article

    VL - 5

    JO - Frontiers in Immunology

    JF - Frontiers in Immunology

    SN - 1664-3224

    IS - MAY

    M1 - 195

    ER -